To study the impact of MYC on conventional and T cell-redirecting therapeutic antibodies, we first inhibited MYC in an extensive panel of DLBCL, BL and MM cell lines using the small molecule 10058-F4. The gene discussed is MYC; the disease is Miyoshi myopathy.